ScripSichuan Kelun Pharmaceutical has won an approval in China for its Merck & Co.-partnered sacituzumab tirumotecan (sac-TMT), a TROP2-targeting antibody-drug conjugate (ADC), which becomes the world’
ScripOnce a key part of its next-generation plans in cancer, Merck & Co . has called a halt to the last remaining Phase III studies of its TIGIT- and LAG-3 targeting immunotherapy assets. The two immu
ScripThe Chinese government has kickstarted a new round of a national drug hunting campaign involving the industry and academia, with the first two programs in lung and breast cancer launched this month. T
ScripBioNTech’s close to $1bn acquisition of Biotheus announced earlier this month marked another big M&A deal between a Chinese biotech and a foreign firm following AstraZeneca’s roughly $1.2bn buyou